Connection

MICHELE REDELL to Xenograft Model Antitumor Assays

This is a "connection" page, showing publications MICHELE REDELL has written about Xenograft Model Antitumor Assays.
  1. Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Blood Adv. 2019 12 23; 3(24):4215-4227.
    View in: PubMed
    Score: 0.034
  2. Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia. Leukemia. 2019 01; 33(1):52-63.
    View in: PubMed
    Score: 0.031
  3. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Mol Ther. 2016 09 29; 24(9):1615-26.
    View in: PubMed
    Score: 0.027
  4. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. J Hematol Oncol. 2016 Mar 12; 9:24.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.